Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution.

Details

This publication is an old version. This notice is replaced by serval:BIB_7FF72A5306B3
Ressource 1 Under indefinite embargo.
UNIL restricted access
State: Public
Version: Final published version
License: All rights reserved
Serval ID
serval:BIB_2EAAEFF3D2E3
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Title
Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution.
Journal
Neuromuscular disorders
Author(s)
Ivanyuk A., García Segarra N., Buclin T., Klein A., Jacquier D., Newman C.J., Bloetzer C.
ISSN
1873-2364 (Electronic)
ISSN-L
0960-8966
Publication state
Published
Issued date
10/2018
Peer-reviewed
Oui
Volume
28
Number
10
Pages
865-867
Language
english
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Abstract
Rhabdomyolysis with myoglobinuria is a recognized complication of dystrophinopathies. It can be triggered by infections, exercise or volatile anesthetics. To our knowledge, it has never been reported in boys with Duchenne muscular dystrophy (DMD) after the administration of bisphosphonates. We report two patients with DMD who presented an apparent transient rhabdomyolysis with myoglobinuria after zoledronate administration. Possible mechanisms could involve hypophosphatemia, a known dose-dependent side effect of bisphosphonates, and/or direct myotoxicity of biphosphonates. Physicians and families should be aware of rhabdomyolysis with myoglobinuria as a potential uncommon side effect of bisphosphonates in DMD, in particular of zoledronate.
Keywords
Adolescent, Bone Density Conservation Agents/adverse effects, Bone Density Conservation Agents/therapeutic use, Humans, Male, Muscular Dystrophy, Duchenne/complications, Muscular Dystrophy, Duchenne/drug therapy, Myoglobinuria/etiology, Zoledronic Acid/adverse effects, Zoledronic Acid/therapeutic use, Duchenne muscular dystrophy, bisphosphonates, myoglobinuria, zoledronate
Pubmed
Web of science
Create date
10/03/2020 17:22
Last modification date
30/10/2023 9:52
Usage data